Calcium tablets trial for PBSC collection

Open-Label, randomized clinical trial of oral calcium tablets to prevent citrate-related adverse effects in peripheral blood progenitor cell collection from healthy donors.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061220096

Enrollment

Registered

2023-02-09

Start date

2023-07-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy donors donor

Interventions

taking tablets before starting peripheral progenitor cell collection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: healthy donors

Exclusion criteria

Exclusion criteria: Those that do not meet the eligibility requirements to be a healthy donor

Design outcomes

Primary

Measure	Time frame
Incidence of citrate-related adverese effect; Grade 1 or higher	—

Secondary

Measure	Time frame
Incidence of citrate-related adverese effect; Grade 2 or higher Incidence of citrate-related adverese effect; Grade 3 or higher Percentage decrease in ionized calcium, potassium, etc. safety	—

Contacts

Public ContactKeiko Fujii

Okayama University Hospital

keikofujii@okayama-u.ac.jp+81-862357768

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026